IngentaConnect Pseudoporphyria as a result of voriconazole use: a case report

Authors: Christopher K. Dolan¹; Mark A. Hall²; David L. Blazes²; Christopher W. Norwood

Source: International Journal of Dermatology, Volume 43, Number 10, October 2004 , pp. 768-771(4)

Abstract:

Voriconazole, a second-generation triazole, has recently been approved by the Food and Drug Administration (FDA) to treat invasive aspergillosis and refractory infections with Scedosporium apiospermum or Fusarium spp. ¹ The reported side-effects of voriconazole include visual changes, headaches, elevated hepatic enzymes, Steven–Johnson syndrome, toxic epidermal necrolysis, chelitis, photosensitivity, discoid lupus erythematosus and anaphylactoid infusion reactions. ^1–9 Pseudoporphyria was first described in association with nalidixic acid. ^10,11 It has the same clinical and histologic features as porphyria cutanea tarda (PCT) but is distinguished by normal porphyrin levels in the serum, urine and stool. We present the case of a patient who developed pseudoporphyria after receiving treatment with voriconazole.

Document Type: Research article

DOI: 10.1111/j.1365-4632.2004.02177.x

Affiliations: 1: From the United States Naval Reserve, Patuxent River Naval Medical Clinic, Patuxent River, MD, USA, National Capital Consortium Dermatology Residency Program, Walter Reed Army Medical Center, Washington DC, and United States Navy, National Naval 2: From the United States Naval Reserve, Patuxent River Naval Medical Clinic, Patuxent River, MD, USA, National Capital Consortium Dermatology Residency Program, Walter Reed Army Medical Center, Washington DC, and United States Navy, National Naval

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax Refund Policy